Strengthening our Advisory Board with addition of Mark McKenna as Strategic Advisor and Peter Libby, MD as a Clinical AdvisorExpanding the Phase ...

Piper Sandler 37th Annual Healthcare Conference details: Fireside Chat Date: Wednesday, December 3, 2025 Time: 4:00 – 4:25 PM ET ...

Retail traders on Stocktwits drove a surge in takeover speculation amid Madrigal’s strong momentum around its liver-disease drug Rezdiffra. ・Fresh analyst target hikes followed new two-year clinical ...

Ventyx Biosciences Inc. (NASDAQ:VTYX) is among the hottest SMID-cap stocks so far in 2025. On November 7, TheFly reported that Canaccord Genuity modestly increased its price target on the company’s ...

Investing.com - H.C. Wainwright upgraded Ventyx Biosciences Inc (NASDAQ:VTYX) from Neutral to Buy on Wednesday, assigning a price target of $18.00. The stock has shown remarkable momentum, with ...

Ventyx Biosciences Inc. (NASDAQ:VTYX) is one of the best NASDAQ stocks under $5 to buy now. On October 22, Ventyx Biosciences announced positive topline results from its Phase 2 study of the oral, ...

Ventyx Biosciences recently announced positive topline results from its Phase 2 trial of VTX3232, showing significant reductions in key inflammatory biomarkers such as hsCRP, IL-6, and Lp(a) in ...

Good day, everyone, and welcome to today's Ventyx business update call. [Operator Instructions] Today's call is being recorded. I will stand by should you need any assistance. It is now my pleasure to ...

An experimental Ventyx Biosciences drug led to statistically significant reductions in blood levels of a protein that’s an indicator of cardiovascular risk, preliminary Phase 2 results that support ...

Ventyx Biosciences Inc (NASDAQ:VTYX) shares are surging Thursday after the company announced positive Phase 2 study results for VTX3232 in patients with obesity and cardiovascular risk factors. What ...